

Publications Etudes et Recherche en Economie de la Santé 2014-2023

1. Lebret T, Bonastre J, Fraslin A, Neuzillet Y, Droupy S, Rebillard X, Vordos D, Guy L, Villers A, Schneider M, Coloby P, Lacoste J, Méjean A, Lacoste J, Descotes JL, Eschwege P, Loison G, Blanché H, Mariani O, Ghaleh B, Mangin A, Sirab N, Groussard K, Radvanyi F, Allory Y, Benhamou S. Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life. *BMJ Open*. 2023 Dec 20;13(12):e075942.
2. Bergerot CD, Bonastre J. Health-related Quality of Life and Cost Effectiveness of Treatment: Components to Be Included in Clinical Decision-making. *Eur Urol Oncol*. 2023 Jun;6(3):349-350.
3. Bayle A, Bonastre J, Chaltiel D, Latino N, Rouleau E, Peters S, Galotti M, Bricalli G, Besse B, Giuliani R. ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe. *Ann Oncol*. 2023 Oct;34(10):934-945.
4. Le Corroller AG, Bonastre J. Patient-reported measures: how useful in health economics? *Eur J Health Econ*. 2023 Feb;24(1):1-4.
5. Palmer S, Borget I, Friede T, Husereau D, Karnon J, Kearns B, Medin E, Peterse EFP, Klijn SL, Verburg-Baltussen EJM, Fenwick E, Borrill J. A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies. *Value Health*. 2023 Feb;26(2):185-192.
6. de Pourville G, Armoiry X, Lavorel A, Bilbault P, Maugendre P, Bensimon L, Beziz D, Blin P, Borget I, Bouée S, Collignon C, Dervaux B, Durand-Zaleski I, Julien M, de Léotoing L, Majed L, Martelli N, Séjourné T, Viprey M. Données et preuves en vie réelle dans l'évaluation des technologies de santé : dans quels cas sont-elles complémentaires, substitutives, ou les seules sources de données par rapport aux essais cliniques ? *Therapie*. 2023 Jan-Feb;78(1):66-80.
7. Roze S, Bertrand N, Eberst L, Borget I. Projecting overall survival in health-economic models: uncertainty and maturity of data. *Curr Med Res Opin*. 2023 Mar;39(3):367-374.
8. Grumberg V, Chouaïd C, Gaudin AF, Le Tourneau C, Marabelle A, Bongiovanni-Delarozière I, Cotté FE, Borget I. Organizational Impact of Immunotherapies in Advanced Cancers in France. *JCO Glob Oncol*. 2023 Aug;9:e2300026.
9. Martin T, Guercio A, Besseau H, Huot L, Guerre P, Atfeh J, Piazza L, Pineau J, Sabatier B, Borget I, Martelli N. Hospital-based health technology assessment of innovative medical devices: insights from a nationwide survey in France. *Int J Technol Assess Health Care*. 2023 Sep 21;39(1):e58.
10. Farah L, Davaze-Schneider J, Martin T, Nguyen P, Borget I, Martelli N. Are current clinical studies on artificial intelligence-based medical devices comprehensive enough to support a full health technology assessment? A systematic review. *Artif Intell Med*. 2023 Jun;140:102547.
11. Jenei K, Raymakers AJN, Bayle A, Berger-Thürmel K, Cherla A, Honda K, Jackson CCGA, Karikios D, Trapani D, Berry S, Gyawali B. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study. *Lancet Oncol*. 2023 Jun;24(6):624-635. doi: 10.1016/S1470-2045(23)00175-4. PMID: 37269843.

12. Di Meglio A, Martin E, Crane TE, Charles C, Barbier A, Raynard B, Mangin A, Tredan O, Bouleuc C, Cottu PH, Vanlemmens L, Segura-Djezzar C, Lesur A, Pistilli B, Joly F, Ginsbourger T, Coquet B, Pauporte I, Jacob G, Sirven A, Bonastre J, Ligibel JA, Michiels S, Vaz-Luis I. A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design. *Trials*. 2022 Mar 4;23(1):193.
13. de Kerangal Q, Kapso R, Morinière S, Laure B, Bonastre J, Moya-Plana A. Sentinel lymph node biopsy versus selective neck dissection in patients with early oral squamous cell carcinoma: A cost analysis. *J Stomatol Oral Maxillofac Surg*. 2022 Jun;123(3):372-376.
14. Or Z, Rococco E, Touré M, Bonastre J. Impact of Competition Versus Centralisation of Hospital Care on Process Quality: A Multilevel Analysis of Breast Cancer Surgery in France. *Int J Health Policy Manag*. 2022 Apr 1;11(4):459-469.
15. Gascon P, Borget I, Comet A, Carton L, Matonti F, Dupont-Benjamin L. Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study). *Eur J Ophthalmol*. 2022 May;32(3):1702-1709.
16. Luyten J, Connolly MP, Verbeke E, Buhler K, Scotland G, Lispi M, Revelli A, Borget I, Cedrin-Durnerin I, D'Hooghe T. Economic evaluation of Medically Assisted Reproduction: An educational overview of methods and applications for healthcare professionals. *Best Pract Res Clin Obstet Gynaecol*. 2022 Dec;85(Pt B):217-228.
17. Farah L, Magne N, Martelli N, Sotton S, Zerbib M, Borget I, Scher N, Guetta T, Chargari C, Bauduceau O, Toledano A. Robot-Assisted Surgery vs Robotic Stereotactic Body Radiotherapy in Prostate Cancer: A Cost-Utility Analysis. *Front Oncol*. 2022 May 24;12:834023.
18. Grumberg V, Chouaïd C, Cotté FE, Jouaneton B, Jolivel R, Gaudin AF, Reynaud D, Assié JB, Borget I. Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France. *J Med Econ*. 2022 Jan-Dec;25(1):691-699.
19. Kandel M, Bardet A, Dalle S, Allayous C, Mortier L, Guillot B, Dutriaux C, Leccia MT, Dalac S, Montaudie H, Saiag P, Legoupil D, Brunet-Possenti F, Arnault JP, Quatrebarbes J, Beylot-Barry M, Maubec E, Lesimple T, Aubin F, Grob JJ, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, Borget I. Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France. *Curr Oncol*. 2022 Nov 27;29(12):9255-9270.
20. Bayle A, Italiano A, Massard C, Blay JY, Marabelle A. Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox. *Eur J Cancer*. 2022 Feb;162:128-129.
21. Brogaard, N., Abdul-Ghani, R., Bayle, A., Henderson, N., Bréant, A, and Steuten, L. (2022) Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies. OHE Consulting Report. Available from <https://www.ohe.org/publications/learnings-assessments-entrectinib-and-larotrectinib-health-technology-assessment#>.
22. Marguet S, Adenis A, Delaine-Clisant S, Penel N, Bonastre J. Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial. *Value Health*. 2021 May;24(5):676-682.

23. Bardet A, Fraslin AM, Marghadi J, Borget I, Faron M, Honoré C, Delalogue S, Albiges L, Planchard D, Ducreux M, Hadoux J, Colomba E, Robert C, Bouhir S, Massard C, Micol JB, Ter-Minassian L, Michiels S, Auperin A, Barlesi F, Bonastre J. Impact of COVID-19 on healthcare organisation and cancer outcomes. *Eur J Cancer*. 2021 Aug;153:123-132.
24. Bayle A, Droin N, Besse B, Zou Z, Boursin Y, Rissel S, Solary E, Lacroix L, Rouleau E, Borget I, Bonastre J. Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting. *Eur J Health Econ*. 2021 Aug;22(6):855-864.
25. Le Cesne A, Blay JY, Cupissol D, Italiano A, Delcambre C, Penel N, Isambert N, Chevreau C, Bompas E, Bertucci F, Chaigneau L, Piperno-Neumann S, Salas S, Rios M, Guillemet C, Bay JO, Ray-Coquard I, Haddag L, Bonastre J, Kapso R, Fraslin A, Bouvet N, Mir O, Foulon S. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. *Ann Oncol*. 2021 Aug;32(8):1034-1044.
26. Foulon S, Cony-Makhoul P, Guerci-Bresler A, Daban M, Kapso R, Tubert-Bitter P, Bonastre J. Health state utility and quality of life measures in patients with chronic myeloid leukemia in France. *Quality of Life research*. 2021 Jul;30(7):2021-2032.
27. Bayle A, Hollebecque A, Pistilli B, Massard C, Marabelle A. Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks. *Eur J Cancer*. 2021 Oct;156:217-221.
28. Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. *Ann Oncol*. 2020 Aug 24;S0923-7534(20)39971-3.
29. Kandel M, Dunant A, Balleyguier C, Bonastre J. Cost-effectiveness of preoperative magnetic resonance imaging to optimize surgery in ductal carcinoma in situ of the breast. *Eur J Radiol*. 2020 Aug;129:109058.
30. Bourgain C, Pourtau L, Mazouni C, Bungener M, Bonastre EJ. Imperfect biomarkers for adjuvant chemotherapy in early stage breast cancer with good prognosis. *Soc Sci Med*. 2020 Feb;246:112735.
31. Legoupil C, Debieuvre D, Marabelle A, Michiels S, Kapso R, Besse B, Bonastre J. A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer. *ERJ Open Res*. 2020 Apr 19;6(2):00174-2019.
32. Coquerelle S, Darlington M, Michel M, Durand M, Borget I, Baffert S, Marino P, Perrier L, Durand-Zaleski I; NGSEco Group. Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments. *Value Health*. 2020 Jul;23(7):898-906.
33. Thivilliers AP, Ladarré R, Merabti O, François C, Fontenay S, van den Brink H, Pineau J, Prognon P, Borget I, Martelli N. The learning curve in transcatheter aortic valve implantation clinical studies: A systematic review. *Int J Technol Assess Health Care*. 2020 Apr;36(2):152-161.

34. Kandel M, Dalle S, Bardet A, Allayous C, Mortier L, Dutriaux C, Guillot B, Leccia MT, Dalac S, Legoupil D, Saiag P, Montaudie H, Arnault JP, Brunet-Possenti F, Grob JJ, DeQuatrebarbes J, Beylot-Barry M, Lesimple T, Aubin F, Maubec E, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, Borget I. Quality-of-life assessment in French patients with metastatic melanoma in real life. *Cancer*. 2020 Feb 1;126(3):611-618.
35. Théhard B, Detournay B, Borget I, Roze S, De Pourvoirville G. Value of a QALY for France: A New Approach to Propose Acceptable Reference Values. *Value Health*. 2020 Aug;23(8):985-993.
36. Bourgain C, Pourtau L, Mazouni C, Bungener M, Bonastre EJ. Imperfect biomarkers for adjuvant chemotherapy in early stage breast cancer with good prognosis. *Soc Sci Med*. 2020 Feb;246:112735. doi: 10.1016/j.socscimed.2019.112735.
37. Foulon S, Cony-Makhoul P, Guerci-Bresler A, Delord M, Solary E, Monnereau A, Bonastre J, Tubert-Bitter P. Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study. *Cancer Med*. 2019 Jun;8(6):3296-3304.
38. Bayle A, Besse B, Annereau M, Bonastre J. Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact? *Eur J Cancer*. 2019 May;113:28-31.
39. Lafuma A, Cotté FE, Le Tourneau C, Emery C, Gaudin AF, Torreton E, Gourmelen J, Bonastre J. Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiaries. *J Med Econ*. 2019 Jul;22(7):698-705.
40. Balleyguier C, Dunant A, Ceugnart L, Kandel M, Chauvet MP, Chérel P, Mazouni C, Henrot P, Rauch P, Chopier J, Zilberman S, Doutriaux-Dumoulin I, Jaffre I, Jalaguier A, Houvenaeghel G, Guérin N, Callonnec F, Chapellier C, Raoust I, Mathieu MC, Rimareix F, Bonastre J, Garbay JR. Preoperative Breast Magnetic Resonance Imaging in Women With Local Ductal Carcinoma in Situ to Optimize Surgical Outcomes: Results From the Randomized Phase III Trial IRCIS. *J Clin Oncol*. 2019 Apr 10;37(11):885-892.
41. Kandel M, Dalle S, Bardet A, Allayous C, Mortier L, Dutriaux C, Guillot B, Leccia MT, Dalac S, Legoupil D, Saiag P, Montaudie H, Arnault JP, Brunet-Possenti F, Grob JJ, DeQuatrebarbes J, Beylot-Barry M, Lesimple T, Aubin F, Maubec E, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, Borget I. Quality-of-life assessment in French patients with metastatic melanoma in real life. *Cancer*. 2019 Oct 22.
42. Lacas B, Bouché O, Etienne PL, Gasmi M, Texereau P, Gargot D, Lombard-Bohas C, Azzedine A, Denis B, Geoffroy P, Auby D, Michel P, Pignon JP, Lepage C, Ducreux M, Borget I. Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial. *Expert Rev Pharmacoecon Outcomes Res*. 2019 Oct;19(5):601-608.
43. Bathily T, Borget I, Rivin Del Campo E, Rivera S, Bourcier C., Partial versus whole breast irradiation: Side effects, patient satisfaction and costs, *Cancer Radiother*. 2019 Apr;23(2):83-91.
44. Delord M, Foulon S, Cayuela JM, Rousselot P, Bonastre J. The rising prevalence of chronic myeloid leukemia in France. *Leuk Res*. 2018; 69:94-99.

45. Marino P, Touzani R, Perrier L, Rouleau E, Kossi DS, Zhaomin Z, Charrier N, Goardon N, Preudhomme C, Durand-Zaleski I, Borget I, Baffert S; NGSEco Group. Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study. *Eur J Hum Genet.* 2018 Mar;26(3):314-323.
46. Espin J, Schlander M, Godman B, Anderson P, Mestre-Ferrandiz J, Borget I, Hutchings A, Flostrand S, Parnaby A, Jommi C. Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates. *Appl Health Econ Health Policy.* 2018 Dec;16(6):803-817.
47. Châteauvieux C, Farah L, Guérot E, Wermert D, Pineau J, Prognon P, Borget I, Martelli N. Single-use flexible bronchoscopes compared with reusable bronchoscopes: Positive organizational impact but a costly solution. *J Eval Clin Pract.* 2018 Jun;24(3):528-535.
48. Lejeune C, Lueza B, Bonastre J; le French costing group. [Economic analysis of multinational clinical trials in oncology]. *Bull Cancer.* 2018 Feb;105(2):204-211.
49. Perrier L; French Costing Group. [Editorial]. *Rev Epidemiol Sante Publique.* 2018 Feb 24. pii: S0398-7620(18)30159-7.
50. Guerre P, Hayes N, Bertaux AC; French Costing Group. [Hospital costs estimation by micro and gross-costing approaches]. *Rev Epidemiol Sante Publique.* 2018 Mar 7. pii: S0398-7620(18)30151-2.
51. Margier J, Baffert S, Le Corroller-Soriano AG; French Costing Group. [Standard or specific unit costs: Which criteria for choosing an economic evaluation of health strategies in multicentric studies?]. *Rev Epidemiol Sante Publique.* 2018 Mar 8. pii: S0398-7620(18)30152-4.
52. Mercier G, Costa N, Dutot C, Riche VP; French Costing Group. [Data sources, the data used, and the modality for collection]. *Rev Epidemiol Sante Publique.* 2018 Mar 9. pii: S0398-7620(18)30160-3.
53. Morelle M, Plantier M, Dervaux B, Pagès A, Deniès F, Havet N, Perrier L; French Costing Group. [Methods for the analysis and treatment of cost data by micro- and gross-costing approaches]. *Rev Epidemiol Sante Publique.* 2018 Mar 9. pii: S0398-7620(18)30158-5.
54. Conversano A, Mazouni C, Maulard A, Gaudin A, Fournier M, Bentivegna E, Rimareix F, Bonastre J. Use of low-thrombin fibrin sealant glue after axillary lymphadenectomy for breast cancer to reduce hospital length and seroma. *Clinical Breast Cancer* 2017; 17(4):293-297.
55. Guyot P, Ades AE, Beasley M, Lueza B, Pignon JP, Welton NJ. Extrapolation of Survival Curves from Cancer Trials Using External Information. *Med Decis Making.* 2017 May;37(4):353-366.
56. Dutot C, Mercier G, Borget I, de Sauvebeuf C, Martelli N. Hospital-based health technology assessment for the adoption of innovative medical devices within French hospitals: opportunities and challenges for industry. *Int J Technol Assess Health Care.* 2017 Jan;33(2):297-302.
57. Martelli N, Devaux C, van den Brink H, Billaux M, Pineau J, Prognon P, Borget I. Harmonizing health technology assessment practices in university hospitals: to what extent is the mini-hta model suitable in the French context? *Int J Technol Assess Health Care.* 2017 Jan;33(2):307-314.

58. Motte AF, Diallo S, van den Brink H, Châteauevieux C, Serrano C, Naud C, Steelandt J, Alsac JM, Aubry P, Cour F, Pellerin O, Pineau J, Prognon P, Borget I, Bonan B, Martelli N. Existing reporting guidelines for clinical trials are not completely relevant for implantable medical devices: a systematic review. *J Clin Epidemiol.* 2017 Nov;91:111-120.
59. Daroles J, Borget I, Suci V, Mazouni C, Delalogue S, Balleyguier C. Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful? *Eur J Cancer.* 2017 Nov;85:23-30.
60. Pagès A, Foulon S, Zou Z, Lacroix L, Lemare F, de Baère T, Massard C, Soria JC, Bonastre J. The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial. *Genetics in Medicine.* 2016; 19(6):683-690.
61. Benhamou S, Bonastre J, Groussard K, Radvanyi F, Allory Y, Leuret T. A prospective multicenter study on bladder cancer: the COBLAnCE cohort. *BMC Cancer.* 2016;16(1):837.
62. Delalogue S, Bonastre J, Borget I, Garbay JR, Fontenay R, Boinon D, Saghatchian M, Mathieu MC, Mazouni C, Rivera S, Uzan C, André F, Dromain C, Boyer B, Pistilli B, Azoulay S, Rimareix F, Bayou EH, Sarfati B, Caron H, Ghouadni A, Leymarie N, Canale S, Mons M, Arfi-Rouche J, Arnedos M, Suci V, Vielh P, Balleyguier C. The challenge of rapid diagnosis in oncology: economic and diagnosis accuracy of a large-scale one-stop breast clinic. *European journal of cancer* 2016 ; 66:131-7.
63. Lassau N, Coiffier B, Kind M, Vilgrain V, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A, Labbe-Devilliers C, Gallix B, Lucidarme O, Ptak Y, Rocher L, Caquot LM, Chagnon S, Marion D, Luciani A, Feutray S, Uzan-Augui J, Benatsou B, Bonastre J, Koscielny S. Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab. *Ann Oncol.* 2016 ; 27(10):1922-8.
64. Marguet S, Mazouni C, Ramaekers BL, Dunant A, Kates R, Jacobs VR, Joore MA, Harbeck N, Bonastre J. European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer. *Eur J Cancer* 2016; 63:168-79.
65. Remon J, Bonastre J, Besse B. The “5000%” case: a glimpse of the lung cancer treatment financial issue. *European respiratory journal* 2016;47(5):1331-3.
66. Ouldamer L, Bonastre J, Brunet-Houdard S, Body G, Giraudeau B, Caille A. Dead space closure with quilting suture versus conventional closure with drainage for the prevention of seroma after mastectomy for breast cancer (QUISERMAS): protocol for a multicentre randomised controlled trial. *BMJ Open* 2016;6(4):e009903.
67. Lueza L, Rotolo F, Bonastre J, Pignon JP, Michiels S. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. *BMC Medical Research Methodology* 2016; 29;16(1):37.
68. Lueza B, Mauguen A, Pignon JP, Rivero-Arias O, Bonastre J. Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study. *PLoS One* 2016 ;11(3):e0150032.
69. Rococo E, Mazouni C, Or Z, Mobillion V, Koon Sun Pat M, Bonastre J. Variation in rates of breast cancer surgery: A national analysis based on French Hospital Episode Statistics. *Eur J Surg Oncol* 2016;42(1):51-8.

70. Martelli N, van den Brink H, Borget I. New French Coverage with Evidence Development for Innovative Medical Devices: Improvements and Unresolved Issues. *Value Health* 2016 Jan;19(1):17-9.
71. Martelli N, Hansen P, van den Brink H, Boudard A, Cordonnier AL, Devaux C, Pineau J, Prognon P, Borget I. Combining multi-criteria decision analysis and mini-health technology assessment: A funding decision-support tool for medical devices in a university hospital setting. *J Biomed Inform.* 2016 Feb;59:201-8.
72. Freyer G, Scotte F, Borget I, Bruyas A, Vainchtock A, Chouaid C. [Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database]. *Bull Cancer.* 2016 Jun;103(6):552-60.
73. Chouaid C, Borget I, Braun E, Bazil ML, Schaetz D, Rémuzat C, Toumi M. French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends. *Target Oncol.* 2016 Aug;11(4):515-34.
74. Billaux M, Borget I, Prognon P, Pineau J, Martelli N. Innovative medical devices and hospital decision making: a study comparing the views of hospital pharmacists and physicians. *Aust Health Rev.* 2016 Jun;40(3):257-261.
75. Borget I, Bonastre J, Catargi B, Déandréis D, Zerdoud S, Rusu D, Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Kelly A, Toubert ME, Leboulleux S, Journeau F, Benhamou E, Schlumberger M. Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in thyroid cancer patients: results from the randomized phase III ESTIMABL trial. *J Clin Oncol* 2015; 33(26):2885-92.
76. Bonastre J, Marguet S, Lueza B, Michiels S, Delalogue S, Saghatchian M. Reply to V.P. Retèl et al, D. Gauchan et al, and C. Rahilly-Tierney et al. *J Clin Oncol.* 2015;33(14):1629-30.
77. Martelli N, Billaux M, Borget I, Pineau J, Prognon P, van den Brink H. Introduction of innovative medical devices at French university hospitals: an overview of hospital-based health technology assessment initiatives. *Int J Technol Assess Health Care.* 2015;31(1-2):12-8.
78. Martelli N, Devaux C, van den Brink H, Pineau J, Prognon P, Borget I. A Systematic Review of the Level of Evidence in Economic Evaluations of Medical Devices: The Example of Vertebroplasty and Kyphoplasty. *PLoS One.* 2015 Dec 10;10(12)
79. Scotte F, Martelli N, Vainchtock A, Borget I. The cost of thromboembolic events in hospitalized patients with breast or prostate cancer in France. *AdvTher.* 2015;32(2):138-47.
80. Luporsi E, Bellocq JP, Barrière J, Bonastre J, Chetritt J, Le Corroller AG, de Cremoux P, Fina F, Gauchez AS, Lamy PJ, Martin PM, Mazouni C, Peyrat JP, Romieu G, Verdoni L, Mazeau-Woynar V, Kassab-Chahmi D. [uPA/PAI-1, Oncotype DX™, MammaPrint®). Prognosis and predictive values for clinical utility in breast cancer management]. *Bull Cancer.* 2015. pii: S0007-4551(15)00203-9.
81. Scotte F, Martelli N, Vainchtock A, Borget I. The cost of thromboembolic events in hospitalized patients with breast or prostate cancer in France. *Adv Ther* 2015. 32;138-47.
82. Bellocq JP, Luporsi E, Barrière J, Bonastre J, Chetritt J, Le Corroller AG, de Crémoux P, Fina F, Gauchez AS, Kassab-Chahmi D, Lamy PJ, Martin PM, Mazouni C, Peyrat JP,

Romieu G, Verdoni L, Mazeau-Woynar V. [uPA/PAI-1, Oncotype DX™, MammaPrint®). Prognosis and predictive values for clinical utility in breast cancer management]. *Ann Pathol.* 2014 Oct;34(5):349-51.

83. Bonastre J, Marguet S, Lueza B, Michiels S, Delalogue S, Saghatchian M. Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer. *J Clin Oncol.* 2014;32(31):3513-9.
84. Chouaid C, Borget I, Vergnenegre A. Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies? *J Clin Oncol* 2014; 32: 3577.
85. Lassau N, Bonastre J, Kind M, Vilgrain V, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A, Labbe-Devilliers C, Gallix B, Lucidarme O, Ptak Y, Rocher L, Caquot LM, Chagnon S, Marion D, Luciani A, Feutray S, Uzan-Augui J, Coiffier B, Benastou B, Koscielny S. Validation of Dynamic Contrast-Enhanced Ultrasound in Predicting Outcomes of Antiangiogenic Therapy for Solid Tumors: The French Multicenter Support for Innovative and Expensive Techniques Study. *Invest Radiol.* 2014;49(12):794-800.
86. Bonastre J, Chevalier J, Van der Laan C, Delibes M, De Pourville G. Access to innovation: is there a difference in the use of expensive anticancer drugs between French hospitals? *Health Policy.* 2014;116(2-3):162-9.
87. Borget I, Pérol M, Pérol D, Lavolé A, Greillier L, Dô P, Westeel V, Crequit J, Léna H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenegre A, Zalcman G, Chouaid C, IFCT-GFPC investigators. Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study. *BMC Cancer* 2014; 14: 953.
88. Chouaid C, Crequit P, Borget I, Vergnenegre A. Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review. *Clinicoecon Outcomes Res.* 2014 Dec 15;7:9-15.
89. Borget I, Antoun S, Chachaty E, Gachot B, Alibay A, Di Palma M, Merad M. Modalités de prise en charge des neutropénies fébriles chez les patients traités pour une néoplasie solide dans le service d'urgence de cancérologie Gustave-Roussy et leurs impacts économiques. *Bull Cancer* 2014 ;101 : 925-31.